T cells made for KRAS-mutant tumors in solid cancers
Part of Cancer clinical trials.
This Phase 1 trial tests an engineered immune cell treatment (“T cells”) made to recognize a specific tumor change (KRAS G12V) in people with advanced solid tumors. It’s intended for cancers that did not respond to standard treatments, and the goal is to see safety and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–75.
- Your advanced solid tumor can’t be removed and has progressed after standard treatment (or you couldn’t tolerate it).
- Your scans show at least one measurable tumor spot.
- Your tumor test shows KRAS G12V mutation AND you also have HLA-A*11:01 (from a tissue/blood type test).
- Your health status is good enough (ECOG 0–1) and you’re expected to live at least 3 months.
- Your blood counts, liver/kidney labs, and oxygen level meet the trial’s safety cutoffs, and you can sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
This trial tests a new type of immune cell therapy called TCR-T that targets a specific genetic change (KRAS mutation) found in some pancreatic, colorectal, and lung cancers. If you have the right genetic markers and previous treatments haven't worked, this study may offer a new option.
This trial tests a personalized cell therapy that uses your own immune cells (T-cells) specially modified to target your tumor. It is for people with advanced solid tumors who have run out of standard treatment options.
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.